Selected Start-Ups (11/2007)
In Vivo briefly summarizes the technologies of these recently founded companies: AlistTech, Altair Therapeutics, CardiAQ Valve Technologies, Orasi Medical, Smart Perfusion and ZEDIRA GMBH.
You may also be interested in...
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
“Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate,” FDA says. Warning submitted in March said falsifying data was found in making batch release decisions related to whether certain sterile ophthalmic drugs contained viable microorganisms.
RTI Health Solutions researchers assessed US FDA review documents over past two years to gauge use of a tool meant to facilitate agency disclosures about what patient experience information it considered.